当前位置: 首页 > 期刊 > 《中国医药导报》 > 2020年第29期
编号:1354495
益肾散结化瘀法治疗IgA肾病的机制探讨
http://www.100md.com 2020年12月14日 中国医药导报 2020年第29期
     安咪 田耘

    [摘要] IgA肾病(IgAN)是免疫介导的原发性肾小球疾病,目前发病率较高,无统一的治疗方案。通过探讨IgAN的中医理论依据,并与肾脏微观病理变化相结合,明确IgAN的基本病机为肾气不足、肾络瘀阻,以益肾散结化瘀立法。研究IgAN的西医发病机制及益肾散结化瘀法的现代实验室研究,发现该法可缓解IgAN的临床症状,防治肾脏病理变化,延缓病情进展。肯定中医治疗本病的疗效,为临床治疗提供参考。

    [关键词] IgA肾病;肾虚;瘀血;水湿;益肾散结化瘀法

    [中图分类号] R277.5? ? ? ? ? [文献标识码] A? ? ? ? ? [文章编号] 1673-7210(2020)10(b)-0131-04

    [Abstract] IgA nephropathy (IgAN) is an immune-mediated primary glomerular disease with a high incidence and no unified treatment plan. By discussing the theoretical basis of IgAN in traditional Chinese medicine and combining it with the microscopic pathological changes of the kidneys, it is clarified that the basic pathogenesis of IgAN is qi-deficiency and stasis of the collaterals in kidney and that the treatment of IgAN is kidney-reinforcing mass-disintegrating and removing blood stasis. With the studies of the pathogenesis of Western medicine of IgAN and the modern laboratory researches of kidney-reinforcing mass-disintegrating and removing blood stasis, it is found that this method can relieve the clinical symptoms of IgAN, prevent and cure the pathological changes of the kidney to delay the progression of the disease ......

您现在查看是摘要页,全文长 14104 字符